Background: Clopidogrel is a prodrug that converts in the liver to an active thiol metabolite, which irreversibly inhibits the platelet P2Y12 adenosine diphosphate receptor. It seems that methadone as CYP2C19 inhibitor affects ticlopidine activity in vivo. This study aimed to test the ability of methadone in changing ticlopidine pharmacokinetics. Methods: We conducted a case–control st...

background: clopidogrel is a prodrug that converts in the liver to an active thiol metabolite, which irreversibly inhibits the platelet p2y12 adenosine diphosphate receptor. it seems that methadone as cyp2c19 inhibitor affects ticlopidine activity in vivo. this study aimed to test the ability of methadone in changing ticlopidine pharmacokinetics. methods: we conducted a case–control study in 10...

Clopidogrel, an inhibitor of platelet aggregation, selectively inhibits the binding of adenosine diphosphate (ADP) to its platelet receptor and the subsequent ADP-mediated activation of the glycoprotein GPIIb/IIIa complex, thereby inhibiting platelet aggregation. Oral bioavailability of clopidogrel is very low (less than 50%), due to its poor water solubility. The aim of this investigation was ...

this study was performed to assess the clopidogrel activity in inhibition of platelet aggregation in suspected angina patients on a daily dosag of 75 mg of clopidogrel for at least 7 days. this clinical trial was conducted in the outpatients department of cardiology, post graduate medical institute, lady reading hospital, peshawar from 15th october 2007 to 20th december 2007. we included 105 su...

background: in patients with acute stroke and middle cerebral artery (mca) stenosis, microembolic signals (mes) can predict further cerebral ischemia. therefore, this study was designed to evaluate the prevalence of mes by transcranial doppler (tcd) in patients with mca stenosis under treatment of aspirin or clopidogrel. methods: a randomized clinical trial was performed on 40 patients with acu...

Clopidogrel, an inhibitor of platelet aggregation, selectively inhibits the binding of adenosine diphosphate (ADP) to its platelet receptor and the subsequent ADP-mediated activation of the glycoprotein GPIIb/IIIa complex, thereby inhibiting platelet aggregation. Oral bioavailability of clopidogrel is very low (less than 50%), due to its poor water solubility. The aim of this investigation was ...

Clopidogrel is an antiplatelet agent currently used for preventing stent thrombosis. Despite certain clinical benefits of clopidogrel in patients undergoing percutaneous coronary intervention (PCI), adequate antiplatelet effect has not been obtained in some patients. The present study was designed to investigate the potential association of ABCB1 (ATP-Binding Cassette, Subfamily B, member1) gen...

BACKGROUND Necrosis of skin flaps is considered as an important complication in reconstructive surgery. We conducted an experimental study to investigate the efficacy of low-molecular weight heparin, clopidogrel and their combination to improve the flap survival. METHODS Forty male, adult Sprague-Dawlay rats were divided randomly into 4 groups. Standard rectangular, distally based dorsal ran...

This study was performed to assess the clopidogrel activity in inhibition of platelet aggregation in suspected angina patients on a daily dosag of 75 mg of clopidogrel for at least 7 days. This clinical trial was conducted in the outpatients department of Cardiology, Post graduate Medical Institute, Lady Reading Hospital, Peshawar from 15th October 2007 to 20th December 2007. We included 105 su...

Thrombotic thrombocytopenic purpura (TTP) is a rare variant of thrombotic microangiopathy. We report case TTP in Nigerian chronic kidney disease (CKD) patient who was previously on clopidogrel. The features resolved soon after clopidogrel withdrawn. Clopidogrel cardio-protective anti-platelet drug used CKD patients at risk dyspepsia. However, its potential to cause should be recognized and cons...